Assessing radiation dose for postoperative radiotherapy in prostate cancer: Real world data

作     者：Asunción Hervás-Morón Jose Domínguez-Rullán Victor Duque Santana Mireia Valero Carmen Vallejo Sonsoles Sancho Juan David García Fuentes Miguel Cámara Gallego Fernando López-Campos 

作者机构：Department of Radiation OncologyHospital Universitario Ramón Y CajalMadrid 28034Spain Department of Medical PhysicsHospital Universitario Ramón Y CajalMadrid 28034Spain 

出 版 物：《World Journal of Clinical Oncology》 (世界临床肿瘤学杂志（英文版）)

年 卷 期：2022年第13卷第7期

页      面：652-662页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Prostate cancer Postoperative radiotherapy Dose intensified Radiation dose Biochemical relapse free survival 

摘      要：BACKGROUND Approximately 30%of patients with localized prostate cancer(PCa)who undergo radical prostatectomy will develop biochemical *** these patients,the only potentially curative treatment is postoperative radiotherapy(PORT)with or without hormone ***,the optimal radiotherapy dose is unknown due to the limited data *** To determine whether the postoperative radiotherapy dose influences biochemical failure-free survival(BFFS)in patients with *** Retrospective analysis of patients who underwent radical prostatectomy for PCa followed by PORT-either adjuvant radiotherapy(ART)or salvage radiotherapy(SRT)-between April 2002 and July *** 2002 to 2010,the prescribed radiation dose to the surgical bed was 66-70 Gy in fractions of 2 Gy;from 2010 until July 2015,the prescribed dose was 70-72 *** were grouped into three categories according to the total dose administered:66-68 Gy,70 Gy,and 72 *** primary endpoint was BFFS,defined as the post-radiotherapy prostatespecific antigen(PSA)nadir+0.2 ng/*** endpoints were overall survival(OS),cancer-specific survival(CSS),and metastasis-free survival(MFS;based on conventional imaging tests).Treatment-related genitourinary(GU)and gastrointestinal(GI)toxicity was evaluated according to Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer ***,we aimed to identify potential prognostic ***,OS,CSS,and MFS were calculated with the Kaplan-Meier method and the log-rank *** and multivariate Cox regression models were performed to explore between-group differences in survival outcome *** A total of 301 consecutive patients were *** these,93(33.6%)received ART and 186(66.4%)SRT;22 patients were excluded due to residual macroscopic disease or local recurrence in the surgical *** this subgroup(n=93),43 patients(46.2%)were Gleason score(GS)≤6,44(47.3%)GS 7,and 6(6.5%)GS≥8;clinical stage